Home/Indications/Oncology/Multiple Myeloma

Multiple Myeloma

Oncology 17 original drugs

Novel Drugs

Reformulations

Drug Targets

Oncology indication. Multiple Myeloma has 17 FDA-approved novel treatments, led by Johnson & Johnson, with 678 active industry clinical trials across 16 drug targets. Explore market leaders, treatments by mechanism, the clinical pipeline, and drug targets below.

Multiple Myeloma Market Leaders

Companies with the most FDA-approved novel Multiple Myeloma drugs.

Phase 3 Readouts Pro

12 active Phase 3 trials with confidence-graded completion dates.

Full calendar →

Q3 2026

Mezigdomide

Bristol-Myers Squibb

Estimated · fresh NCT05552976

Q3 2026

Elranatamab

Pfizer

Estimated · fresh NCT06152575

Q3 2026

Pomalidomide

AbbVie

Estimated · stale NCT03539744

Unlock 9 more readouts with confidence-graded estimates

Upgrade to Pro

Anchored on CT.gov primary completion date. Topline announcements typically precede this by 3–9 months. Confidence labels combine date type (ACTUAL/ESTIMATED) with last-update freshness.

Multiple Myeloma Treatments by Mechanism

Top 12 mechanisms across 131 industry trials with a known mechanism of action.

See full pipeline →

BCMA/CD3

10 trials 8 active 2 sponsors

Nuclear Export Inhibitor

8 trials 4 active 3 sponsors

CD38-directed Cytolytic Antibody

19 trials 3 active 5 sponsors

Proteasome Inhibitor

26 trials 2 active 10 sponsors

Thalidomide Analog

25 trials 2 active 5 sponsors

Corticosteroid

9 trials 2 active 6 sponsors

BCL-2 Inhibitor

7 trials 2 active 2 sponsors

BCMA

1 trials 1 active 1 sponsor

SLAMF7-directed Immunostimulatory Antibody

8 trials 2 sponsors

Programmed Death Receptor-1 Blocking Antibody

7 trials 2 sponsors

Kinase Inhibitor

7 trials 4 sponsors

Histone Deacetylase Inhibitor

4 trials 1 sponsor

MoA derived from FDA pharmClassEpc when intervention matches an approved drug. Codenamed clinical-stage assets without an approved counterpart show "—" and aren't grouped here — they're still in the phase tables below.

Multiple Myeloma Clinical Pipeline by Phase

722 industry-sponsored trials across 238 sponsors

View full landscape →

Showing 12 of 12 trials

Sponsor	Asset	MoA	Status	Primary Completion	NCT
Johnson & Johnson Private Limited	Teclistamab	—	RECRUITING	2026-11-03	NCT07030517
Pfizer	Elranatamab	BCMA/CD3	RECRUITING	2032-02-22	NCT06057402
Johnson & Johnson	Cilta-cel	—	RECRUITING	2037-07-29	NCT05201781
Regeneron	Linvoseltamab	—	NOT YET RECRUITING	2027-10-11	NCT07609940
Amgen	Drug: Carfilzomib + Dexamethasone	—	COMPLETED	2023-03-23	NCT03934684
Johnson & Johnson Private Limited	Daratumumab	CD38-directed Cytolytic Antibody [EPC]	COMPLETED	2022-07-16	NCT03768960
CASI Pharmaceuticals (China) Co., Ltd.	Melphalan Hydrochloride for Injection	—	COMPLETED	2021-07-08	NCT06425276
Takeda	Ixazomib	—	COMPLETED	2021-05-28	NCT03416374
Johnson & Johnson Taiwan Ltd	Bortezomib	Proteasome Inhibitor [EPC]	COMPLETED	2015-07	NCT02268890
Takeda	Ixazomib	—	TERMINATED	2026-03-30	NCT03173092
Takeda	Ixazomib	—	WITHDRAWN	2026-12-31	NCT05183139
DFINE Inc.	—	—	WITHDRAWN	—	NCT01410929

Showing 100 of 121 trials (top 100 by completion date — export for full list)

Sponsor	Asset	MoA	Status	Primary Completion	NCT
Pfizer	Elranatamab	BCMA/CD3	RECRUITING	2026-08-30	NCT06152575
Guangzhou Gloria Biosciences Co., Ltd.	Motixafortide+G-CSF	—	RECRUITING	2026-12-31	NCT06514508
Bristol-Myers Squibb	mezigdomide	—	RECRUITING	2027-01-10	NCT05519085
Hangzhou Sumgen Biotech Co., Ltd.	SG301 Injection	—	RECRUITING	2027-03-31	NCT06508983
Nanjing IASO Biotechnology Co., Ltd.	Equecabtagene Autoleucel Injection	—	RECRUITING	2027-08	NCT06464991
Celltrion	CT-P44(Daratumumab)	—	RECRUITING	2027-11-15	NCT06952478
AbbVie	Etentamig	—	RECRUITING	2027-12	NCT06158841
Qilu Pharmaceutical Co., Ltd.	QLS32015	—	RECRUITING	2027-12	NCT07138209
Sinocelltech Ltd.	SCTC21C	—	RECRUITING	2027-12	NCT07297329
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company	BMS-986393	—	RECRUITING	2027-12-30	NCT06615479
AstraZeneca	AZD0120	—	RECRUITING	2028-06-14	NCT07391657
Kite, A Gilead Company	Anitocabtagene Autoleucel	—	RECRUITING	2028-07	NCT06413498
Grifols Biologicals, LLC	Gamunex-C, 10% Injectable Solution	—	RECRUITING	2028-08-31	NCT07582432
Takeda	IGI, 10%	—	RECRUITING	2028-09-11	NCT06980480
Roche	Cevostamab	—	RECRUITING	2028-10-31	NCT07555938
Johnson & Johnson	JNJ-79635322	—	RECRUITING	2028-12-12	NCT07258511
Shandong New Time Pharmaceutical Co., LTD	F182112 single-agent	—	RECRUITING	2029-01-25	NCT07579234
Johnson & Johnson	Daratumumab	CD38-directed Cytolytic Antibody [EPC]	RECRUITING	2029-01-31	NCT05438043
Genrix (Shanghai) Biopharmaceutical Co., Ltd.	GR1803 injection	—	RECRUITING	2029-03	NCT07452198
Bristol-Myers Squibb	Iberdomide	—	RECRUITING	2029-03-15	NCT05827016
Johnson & Johnson	JNJ-79635322	—	RECRUITING	2029-04-29	NCT07518186
Regeneron	Linvoseltamab	—	RECRUITING	2029-05-21	NCT07222761
Pfizer	Elranatamab	BCMA/CD3	RECRUITING	2030-10-18	NCT05623020
GSK	Belantamab mafodotin	—	RECRUITING	2031-04-28	NCT06679101
Johnson & Johnson	Teclistamab	—	RECRUITING	2031-04-30	NCT05552222
Regeneron	Linvoseltamab	—	RECRUITING	2033-04-19	NCT05730036
Regeneron	Linvoseltamab	—	RECRUITING	2033-07-27	NCT07393282
AbbVie	Etentamig	—	RECRUITING	2042-01	NCT07095452
Pfizer	Elranatamab	BCMA/CD3	RECRUITING	2026-04-27	NCT05020236
Johnson & Johnson	Talquetamab	—	RECRUITING	2026-04-01	NCT06208150
Biocad	BCD-264	—	RECRUITING	2025-01	NCT06296121
Bristol-Myers Squibb	Mezigdomide	—	ACTIVE NOT RECRUITING	2026-07-18	NCT05552976
AbbVie	Pomalidomide	Thalidomide Analog [EPC]	ACTIVE NOT RECRUITING	2026-08	NCT03539744
Johnson & Johnson	Talquetamab	—	ACTIVE NOT RECRUITING	2027-07-30	NCT05455320
AbbVie	Venetoclax	BCL-2 Inhibitor [EPC]	ACTIVE NOT RECRUITING	2027-08	NCT03844048
Pfizer	Elranatamab	BCMA/CD3	ACTIVE NOT RECRUITING	2027-08-04	NCT05317416
Bristol-Myers Squibb	Dexamethasone	Corticosteroid [EPC]	ACTIVE NOT RECRUITING	2027-11-16	NCT04975997
Johnson & Johnson	Daratumumab	CD38-directed Cytolytic Antibody [EPC]	ACTIVE NOT RECRUITING	2028-12-08	NCT05083169
Johnson & Johnson	Bortezomib	Proteasome Inhibitor [EPC]	ACTIVE NOT RECRUITING	2029-02-14	NCT04923893
Antengene Corporation	—	—	ACTIVE NOT RECRUITING	2025-12-31	NCT04939142
Johnson & Johnson	Teclistamab	—	ACTIVE NOT RECRUITING	2025-10-13	NCT05572515
Bristol-Myers Squibb	idecabtagene vicleucel	BCMA	ACTIVE NOT RECRUITING	2025-08-11	NCT06045806
GSK	Belantamab mafodotin	—	ACTIVE NOT RECRUITING	2024-05-27	NCT06956170
Johnson & Johnson	Cilta-cel	—	ACTIVE NOT RECRUITING	2024-05-01	NCT04181827
GSK	Belantamab mafodotin	—	ACTIVE NOT RECRUITING	2024-04-03	NCT06868654
GSK	Belantamab mafodotin	—	ACTIVE NOT RECRUITING	2024-04-03	NCT06868667
GSK	Belantamab mafodotin	—	ACTIVE NOT RECRUITING	2024-01-29	NCT04484623
GSK	Belantamab mafodotin	—	ACTIVE NOT RECRUITING	2023-10-02	NCT04246047
GSK	Belantamab mafodotin	—	ACTIVE NOT RECRUITING	2022-09-12	NCT04162210
BioLineRx, Ltd.	BL-8040 1.25 mg/kg + G-CSF	—	ACTIVE NOT RECRUITING	2020-12-22	NCT03246529
Shanghai Henlius Biotech	HLX15-IV	—	NOT YET RECRUITING	2027-07	NCT06895512
Keymed Biosciences Co.Ltd	CM336 Injection	—	NOT YET RECRUITING	2027-09	NCT07181239
Qilu Pharmaceutical Co., Ltd.	QL2109	—	NOT YET RECRUITING	2027-12	NCT06742138
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	TQB2934 injection	—	NOT YET RECRUITING	2028-12	NCT07569757
Innovent Biologics (Suzhou) Co. Ltd.	Pomalidomide Capsules	—	NOT YET RECRUITING	2029-05-31	NCT07623798
Johnson & Johnson	Ramantamig	—	NOT YET RECRUITING	2030-09-04	NCT07665450
Bristol-Myers Squibb	bb2121	—	COMPLETED	2026-04-13	NCT03651128
TJ Biopharma Co., Ltd.	TJ202, Lenalidomide and Dexamethasone	—	COMPLETED	2024-06-30	NCT03952091
Johnson & Johnson	Daratumumab	CD38-directed Cytolytic Antibody [EPC]	COMPLETED	2024-05-07	NCT03652064
Johnson & Johnson	Daratumumab SC: daratumumab + rHuPH20	—	COMPLETED	2024-05-01	NCT03301220
Johnson & Johnson	Daratumumab	CD38-directed Cytolytic Antibody [EPC]	COMPLETED	2024-04-04	NCT03901963
Millennium Pharmaceuticals, Inc.	Ixazomib	—	COMPLETED	2023-12-06	NCT03748953
Amgen	Carfilzomib	Proteasome Inhibitor [EPC]	COMPLETED	2023-03-31	NCT03859427
Bristol-Myers Squibb	Pomalidomide	Thalidomide Analog [EPC]	COMPLETED	2022-05-09	NCT01734928
Bristol-Myers Squibb	Nivolumab	Programmed Death Receptor-1 Blocking Antibody [EPC]	COMPLETED	2022-03-09	NCT02726581
AbbVie	Venetoclax	BCL-2 Inhibitor [EPC]	COMPLETED	2021-03-15	NCT02755597
Bristol-Myers Squibb	Lenalidomide	Thalidomide Analog [EPC]	COMPLETED	2020-10-12	NCT02112175
Johnson & Johnson	Velcade	Proteasome Inhibitor [EPC]	COMPLETED	2020-07-02	NCT03217812
Karyopharm Therapeutics Inc	Selinexor	Nuclear Export Inhibitor [EPC]	COMPLETED	2020-02-18	NCT03110562
Bristol-Myers Squibb	Pomalidomide	Thalidomide Analog [EPC]	COMPLETED	2019-12-11	NCT01712789
Millennium Pharmaceuticals, Inc.	Ixazomib	—	COMPLETED	2019-12-02	NCT01850524
Johnson & Johnson	Daratumumab	CD38-directed Cytolytic Antibody [EPC]	COMPLETED	2019-10-07	NCT03234972
Bristol-Myers Squibb	Lenalidomide	Thalidomide Analog [EPC]	COMPLETED	2019-10-01	NCT01335399
Takeda	Ixazomib	—	COMPLETED	2019-08-12	NCT02312258
Amgen	Dexamethasone	Corticosteroid [EPC]	COMPLETED	2019-07-14	NCT03158688
Johnson & Johnson	Dara SC	—	COMPLETED	2019-06-27	NCT03277105
Amgen	Dexamethasone	Corticosteroid [EPC]	COMPLETED	2018-11-05	NCT03029234
Johnson & Johnson	Daratumumab	CD38-directed Cytolytic Antibody [EPC]	COMPLETED	2018-10-24	NCT03357952
Johnson & Johnson	Daratumumab IV	—	COMPLETED	2018-09-24	NCT02252172
Johnson & Johnson	Bortezomib	Proteasome Inhibitor [EPC]	COMPLETED	2018-05-07	NCT02811978
Takeda	Ixazomib Citrate	Proteasome	COMPLETED	2018-04-16	NCT02181413
Johnson & Johnson	Velcade	Proteasome Inhibitor [EPC]	COMPLETED	2017-11-21	NCT02195479
PharmaMar	Plitidepsin	—	COMPLETED	2017-11	NCT01102426
Amgen	Carfilzomib	Proteasome Inhibitor [EPC]	COMPLETED	2017-06-15	NCT02412878
Amgen	Denosumab	RANK Ligand Inhibitor [EPC]	COMPLETED	2016-07-19	NCT01345019
Amgen	Carfilzomib	Proteasome Inhibitor [EPC]	COMPLETED	2016-07-15	NCT01818752
Bristol-Myers Squibb	Lenalidomide and low-dose dexamethasone	—	COMPLETED	2016-07-14	NCT00689936
Johnson & Johnson	Daratumumab	CD38-directed Cytolytic Antibody [EPC]	COMPLETED	2016-03-07	NCT02076009
Janssen-Cilag International NV	bortezomib (optimized retreatment)	—	COMPLETED	2016-02	NCT01910987
Johnson & Johnson	Daratumumab	CD38-directed Cytolytic Antibody [EPC]	COMPLETED	2016-01-11	NCT02136134
Janssen Scientific Affairs, LLC	Thalidomide	Cereblon	COMPLETED	2015-12-30	NCT01539083
Novartis	Panobinostat	—	COMPLETED	2015-07-30	NCT01023308
Amgen	Carfilzomib	Proteasome Inhibitor [EPC]	COMPLETED	2014-11-10	NCT01568866
Takeda	Ixazomib	—	COMPLETED	2014-10-01	NCT01564537
Bristol-Myers Squibb	Lenalidomide	Thalidomide Analog [EPC]	COMPLETED	2014-09-02	NCT01239797
Bristol-Myers Squibb	pomalidomide	Thalidomide Analog [EPC]	COMPLETED	2014-07-31	NCT01324947
Amgen	Carfilzomib	Proteasome Inhibitor [EPC]	COMPLETED	2014-07	NCT01302392
Amgen	Dexamethasone	Corticosteroid [EPC]	COMPLETED	2014-06-16	NCT01080391
Oncotherapeutics	armodafinil	DAT	COMPLETED	2013-06	NCT01160380
Bristol-Myers Squibb	pomalidomide	Thalidomide Analog [EPC]	COMPLETED	2013-03-01	NCT01311687

Showing 100 of 300 trials (top 100 by completion date — export for full list)

Sponsor	Asset	MoA	Status	Primary Completion	NCT
Bristol-Myers Squibb	CC-92480	—	RECRUITING	2026-10-12	NCT05372354
Nanjing Leads Biolabs Co.,Ltd	LBL-034 for Injection	—	RECRUITING	2026-10-20	NCT06049290
Innovent Biologics (Suzhou) Co. Ltd.	IBI3003	—	RECRUITING	2026-10-31	NCT06083207
BeOne Medicines	Sonrotoclax	—	RECRUITING	2026-11	NCT04973605
OriCell Therapeutics Co., Ltd.	OriCAR-017	—	RECRUITING	2026-11-30	NCT06182696
Keymed Biosciences Co.Ltd	CM336_group 1	—	RECRUITING	2026-12	NCT05299424
Zhejiang ACEA Pharmaceutical Co. Ltd.	STI-6129	—	RECRUITING	2026-12-31	NCT05565807
Chongqing Precision Biotech Co., Ltd	BCMA targeted prime CAR-T cells	—	RECRUITING	2026-12-31	NCT04776330
Chongqing Precision Biotech Co., Ltd	BCMA CAR-T cells	—	RECRUITING	2026-12-31	NCT04271644
Beijing Biotech	Autologous CD19/CD22 dual-target CAR-T module	—	RECRUITING	2027-03-14	NCT07523555
CellCentric Ltd.	CCS1477	—	RECRUITING	2027-03-31	NCT04068597
Bristol-Myers Squibb	Elranatamab	BCMA/CD3	RECRUITING	2027-05-31	NCT06988488
Johnson & Johnson	JNJ-79635322	—	RECRUITING	2027-06-14	NCT07266441
Sumitomo Pharma America, Inc.	Enzomenib	—	RECRUITING	2027-06-30	NCT04988555
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company	Arlocabtagene Autoleucel	—	RECRUITING	2027-06-30	NCT06297226
AstraZeneca	AZD0305	—	RECRUITING	2027-08-16	NCT06106945
AstraZeneca	AZD0120	—	RECRUITING	2027-08-31	NCT05850234
Qilu Pharmaceutical Co., Ltd.	QLS32015	—	RECRUITING	2027-11	NCT07018050
Karyopharm Therapeutics Inc	Selinexor	Nuclear Export Inhibitor [EPC]	RECRUITING	2028-01	NCT04414475
Johnson & Johnson	Cilta-cel	—	RECRUITING	2028-04-12	NCT07149857
Shandong New Time Pharmaceutical Co., LTD	F182112+P	—	RECRUITING	2028-05-20	NCT07312188
Roche	Cevostamab	—	RECRUITING	2028-07-31	NCT05583617
CellCentric Ltd.	Inobrodib	—	RECRUITING	2029-12-01	NCT07096778
GSK	Unconjugated belantamab antibody	—	RECRUITING	2029-12-03	NCT05714839
C4 Therapeutics, Inc.	Cemsidomide	—	RECRUITING	2030-03	NCT07284758
Johnson & Johnson	Talquetamab	—	RECRUITING	2030-05-30	NCT06500884
ModernaTX, Inc.	mRNA-2808	—	RECRUITING	2030-06-17	NCT07116616
GSK	Belantamab mafodotin	—	RECRUITING	2030-08-30	NCT07227311
AbbVie	ABBV-453	—	RECRUITING	2030-12	NCT06953960
Regeneron	Linvoseltamab	—	RECRUITING	2032-05-18	NCT06140524
Regeneron	Linvoseltamab	—	RECRUITING	2033-03-30	NCT03761108
Regeneron	Linvoseltamab	—	RECRUITING	2033-09-30	NCT07455851
Regeneron	Linvoseltamab	—	RECRUITING	2033-11-11	NCT06669247
Regeneron	Linvoseltamab	—	RECRUITING	2035-11-02	NCT05828511
AbbVie	Etentamig	—	RECRUITING	2036-02	NCT06892522
Starton Therapeutics, Inc	Lenalidomide	Thalidomide Analog [EPC]	RECRUITING	2026-05-31	NCT06087653
Oncotherapeutics	Venetoclax	BCL-2 Inhibitor [EPC]	RECRUITING	2026-04-30	NCT06115135
Gracell Biotechnologies (Shanghai) Co., Ltd.	GC012F	—	RECRUITING	2026-03-02	NCT06235229
Chengdu Zenitar Biomedical Technology Co., Ltd	Purinostat Mesylate 4 mg/m2	—	RECRUITING	2026-02-01	NCT06484829
Biocad	BCD-248	—	RECRUITING	2026-02	NCT06668792
Beijing Mabworks Biotech Co., Ltd.	MBS314 Injection	—	RECRUITING	2026-02	NCT06232096
DexTech Medical AB	ODX (Osteodex)	—	RECRUITING	2026-01-30	NCT06616389
Indapta Therapeutics, INC.	IDP-023	—	RECRUITING	2025-12-30	NCT06119685
GI Cell, Inc.	GIC-102	—	RECRUITING	2025-12-30	NCT05880043
IDP Discovery Pharma S.L.	IDP-121	—	RECRUITING	2025-12-22	NCT05908409
Heidelberg Pharma AG	HDP-101	—	RECRUITING	2025-08	NCT04879043
Hrain Biotechnology Co., Ltd.	Human BCMA Targeted T Cells Injection	—	RECRUITING	2025-07-31	NCT05594797
Shanghai AbelZeta Ltd.	B-cell maturation antigen (BCMA) directed chimeric antigen receptor (CAR)-T cell	—	RECRUITING	2024-07	NCT05521802
Johnson & Johnson	JNJ-68284528	—	ACTIVE NOT RECRUITING	2026-08-04	NCT04133636
Johnson & Johnson	Cilta-cel	—	ACTIVE NOT RECRUITING	2026-08-31	NCT06550895
Bristol-Myers Squibb	CC-92480	—	ACTIVE NOT RECRUITING	2026-11-30	NCT03989414
Kite, A Gilead Company	anitocabtagene-autoleucel	—	ACTIVE NOT RECRUITING	2026-12	NCT05396885
Roche	Cevostamab	—	ACTIVE NOT RECRUITING	2027-02-26	NCT05535244
Karyopharm Therapeutics Inc	Selinexor	Nuclear Export Inhibitor [EPC]	ACTIVE NOT RECRUITING	2027-04	NCT02343042
Genrix (Shanghai) Biopharmaceutical Co., Ltd.	GR1803 injection	—	ACTIVE NOT RECRUITING	2027-05-12	NCT06566547
AbbVie	Carfilzomib	Proteasome Inhibitor [EPC]	ACTIVE NOT RECRUITING	2027-06	NCT02899052
Johnson & Johnson	Cilta-cel	—	ACTIVE NOT RECRUITING	2030-09-02	NCT06577025
AbbVie	Dexamethasone	Corticosteroid [EPC]	ACTIVE NOT RECRUITING	2031-05	NCT03314181
Regeneron	Linvoseltamab	—	ACTIVE NOT RECRUITING	2033-01-25	NCT05955508
Cellectar Biosciences, Inc.	Iopofosine I 131 single dose	—	ACTIVE NOT RECRUITING	2026-06-22	NCT02952508
US Oncology Research	Selinexor	Nuclear Export Inhibitor [EPC]	ACTIVE NOT RECRUITING	2026-05-31	NCT04782687
AbbVie	TNB-383B	—	ACTIVE NOT RECRUITING	2026-05	NCT03933735
Sanofi	Isatuximab	—	ACTIVE NOT RECRUITING	2025-12-22	NCT05704049
Sorrento Therapeutics, Inc.	STI-6129	—	ACTIVE NOT RECRUITING	2025-12	NCT05308225
GSK	Belantamab mafodotin	—	ACTIVE NOT RECRUITING	2025-04-17	NCT04126200
GSK	Belantamab mafodotin	—	ACTIVE NOT RECRUITING	2025-04-17	NCT07084896
GSK	Belantamab mafodotin	—	ACTIVE NOT RECRUITING	2025-04-17	NCT07217184
GSK	Belantamab mafodotin	—	ACTIVE NOT RECRUITING	2025-04-17	NCT07217119
GSK	Belantamab mafodotin	—	ACTIVE NOT RECRUITING	2025-04-17	NCT07150104
GSK	Belantamab mafodotin	—	ACTIVE NOT RECRUITING	2025-04-17	NCT07150091
Otsuka Pharmaceutical Co., Ltd.	OPC-415	—	ACTIVE NOT RECRUITING	2025-04-09	NCT04649073
Johnson & Johnson	Talquetamab	—	ACTIVE NOT RECRUITING	2025-03-18	NCT04586426
CARsgen Therapeutics Co., Ltd.	zevor-cel	—	ACTIVE NOT RECRUITING	2024-12-31	NCT03915184
MitoImmune Therapeutics	MIT-001	—	ACTIVE NOT RECRUITING	2024-06-30	NCT05493800
Bristol-Myers Squibb	CC-220	—	ACTIVE NOT RECRUITING	2024-05-09	NCT02773030
Pfizer	Elranatamab (PF-06863135)	—	ACTIVE NOT RECRUITING	2022-06-17	NCT04649359
Genrix (Shanghai) Biopharmaceutical Co., Ltd.	GR1803 injection	—	NOT YET RECRUITING	2026-07-31	NCT07090954
CARsgen Therapeutics Co., Ltd.	CT071	—	NOT YET RECRUITING	2027-06-15	NCT06333509
Hangzhou Sumgen Biotech Co., Ltd.	SG2918	—	NOT YET RECRUITING	2027-09-30	NCT07454187
Fortvita Biologics (USA)Inc.	IBI3003	—	NOT YET RECRUITING	2027-12-31	NCT07336472
Johnson & Johnson	Ramantamig	—	NOT YET RECRUITING	2027-12-31	NCT07589634
Biotroy Therapeutics	BT02	—	NOT YET RECRUITING	2028-01	NCT07107204
Hebei Senlang Biotechnology Inc., Ltd.	Autologous BCMA-targeting CAR T cells	—	NOT YET RECRUITING	2028-02-01	NCT07421856
GSK	Belantamab mafodotin	—	NOT YET RECRUITING	2029-02-28	NCT07614360
Nanjing IASO Biotechnology Co., Ltd.	Fully Human BCMA Chimeric Antigen Receptor Autologous T Cell Injection (Eque-cel)	—	NOT YET RECRUITING	2029-08-31	NCT07510100
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.	SYHX1903	—	NOT YET RECRUITING	2026-06-20	NCT05055791
Bristol-Myers Squibb	Elotuzumab	SLAMF7-directed Immunostimulatory Antibody [EPC]	COMPLETED	2026-02-23	NCT02719613
Bristol-Myers Squibb	bb2121	—	COMPLETED	2026-01-15	NCT03601078
GPCR Therapeutics, Inc.	GPC-100	—	COMPLETED	2025-09-30	NCT05561751
Roche	Forimtamig	—	COMPLETED	2025-07-08	NCT06055075
Genrix (Shanghai) Biopharmaceutical Co., Ltd.	GR1803 injection	—	COMPLETED	2025-05-20	NCT07102706
Regeneron	REGN5459	—	COMPLETED	2025-05-01	NCT04083534
Bristol-Myers Squibb	Pomalidomide	Thalidomide Analog [EPC]	COMPLETED	2025-04-30	NCT01946477
Cyteir Therapeutics, Inc.	CYT-0851	—	COMPLETED	2024-11-30	NCT03997968
Karyopharm Therapeutics Inc	KPT-8602	—	COMPLETED	2024-08-31	NCT02649790
GSK	Belantamab mafodotin	—	COMPLETED	2024-08-19	NCT05064358
Takeda	Ixazomib	—	COMPLETED	2024-07-03	NCT02924272
Bristol-Myers Squibb	bb2121	—	COMPLETED	2023-12-20	NCT03361748
Janssen Scientific Affairs, LLC	Cilta-cel	—	COMPLETED	2023-11-30	NCT05347485
Pfizer	Elranatamab	BCMA/CD3	COMPLETED	2023-08-06	NCT05228470

Showing 100 of 289 trials (top 100 by completion date — export for full list)

Sponsor	Asset	MoA	Status	Primary Completion	NCT
OriCell Therapeutics Co., Ltd.	OriCAR-017	—	RECRUITING	2026-12-12	NCT06271252
Newave Pharmaceutical Inc	LP-118	—	RECRUITING	2026-12-31	NCT04771572
Excyte Biopharma Ltd	YKST02	—	RECRUITING	2026-12-31	NCT06574568
Kelonia Therapeutics, Inc.	KLN-1010	—	RECRUITING	2027-03	NCT07075185
Oncotherapeutics	Selinexor	Nuclear Export Inhibitor [EPC]	RECRUITING	2027-04-01	NCT06225310
Pfizer	Elranatamab	BCMA/CD3	RECRUITING	2027-04-10	NCT06215118
Johnson & Johnson	JNJ-79635322	—	RECRUITING	2027-04-19	NCT05652335
Shanghai Henlius Biotech	HLX15-SC-Rd	—	RECRUITING	2027-05-25	NCT07477587
Ichnos Sciences SA	ISB 2001	—	RECRUITING	2027-07	NCT05862012
Roche	Cevostamab	—	RECRUITING	2027-07-31	NCT05927571
Suzhou Suncadia Biopharmaceuticals Co., Ltd.	SHR-9539 for injection	—	RECRUITING	2027-07-31	NCT06484777
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.	TQB2934 injection (subcutaneous injection)	—	RECRUITING	2027-10	NCT07179679
Johnson & Johnson	JNJ-79635322	—	RECRUITING	2027-11-19	NCT06768489
Sichuan Baili Pharmaceutical Co., Ltd.	BL-M24D1	—	RECRUITING	2027-12	NCT07255898
Caribou Biosciences, Inc.	CB-011	—	RECRUITING	2027-12	NCT05722418
K36 Therapeutics, Inc.	Cohort A1 & A2: KTX-1001	—	RECRUITING	2027-12-31	NCT05651932
Chongqing Precision Biotech Co., Ltd	Invivo CAR-T	—	RECRUITING	2027-12-31	NCT07239323
O&D BioTech Group CO., Limited	Chimeric antigen receptor T cell O&D-001 injection targeting BCMA and GPRC5D	—	RECRUITING	2028-03-28	NCT07369895
Shanghai Hengrui Pharmaceutical Co., Ltd.	SHR-3836 administered as multiple doses.	—	RECRUITING	2028-04	NCT07490613
Regeneron	Linvoseltamab	—	RECRUITING	2028-04-11	NCT05137054
AstraZeneca	AZD0120	—	RECRUITING	2028-05-26	NCT07073547
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company	BMS-986393	—	RECRUITING	2028-08-01	NCT06121843
Roche	Cevostamab	—	RECRUITING	2028-11-15	NCT06934044
C4 Therapeutics, Inc.	Cemsidomide	—	RECRUITING	2028-12	NCT07280013
AbbVie	Etentamig (ABBV-383)	—	RECRUITING	2029-08	NCT05650632
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company	BMS-986453	—	RECRUITING	2030-05-02	NCT06153251
Roche	RO7851624	—	RECRUITING	2030-07-01	NCT07558915
AbbVie	ABBV-438	—	RECRUITING	2031-11	NCT07409246
AbbVie	Etentamig	—	RECRUITING	2036-03	NCT06896916
Opna Bio LLC	OPN-6602	—	RECRUITING	2026-07	NCT06433947
iCell Gene Therapeutics	BCMA-CD19 cCAR T cells	—	RECRUITING	2026-07	NCT04162353
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.	HDP-101	—	RECRUITING	2026-06-30	NCT07529782
Jiangsu Simcere Pharmaceutical Co., Ltd.	SIM0500	—	RECRUITING	2026-06-30	NCT06375044
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.	TQB2029 injection	—	RECRUITING	2026-03	NCT06700395
Nanjing IASO Biotechnology Co., Ltd.	CAR-GPRC5D	—	RECRUITING	2025-09-01	NCT05759793
Luminary Therapeutics	Autologous CAR-T cell therapy expressing the BAFF-ligand.	—	RECRUITING	2025-07-31	NCT05546723
Oncotherapeutics	Ruxolitinib Oral Tablet [Jakafi]	—	RECRUITING	2024-09	NCT03110822
Cullinan Therapeutics Inc.	CLN-619	—	ACTIVE NOT RECRUITING	2026-09	NCT06381141
C4 Therapeutics, Inc.	cemsidomide	—	ACTIVE NOT RECRUITING	2026-09-30	NCT04756726
Roche	Cevostamab	—	ACTIVE NOT RECRUITING	2026-11-18	NCT05646836
Jiangsu HengRui Medicine Co., Ltd.	HRS-3738	—	ACTIVE NOT RECRUITING	2026-12-30	NCT05363800
Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)	MK-4002	—	ACTIVE NOT RECRUITING	2026-12-31	NCT04184050
AbbVie	Subcutaneous (SC) Etentamig	—	ACTIVE NOT RECRUITING	2027-02	NCT06223516
Johnson & Johnson	Teclistamab	—	ACTIVE NOT RECRUITING	2027-02-28	NCT06425991
Johnson & Johnson	Daratumumab	CD38-directed Cytolytic Antibody [EPC]	ACTIVE NOT RECRUITING	2027-04-07	NCT04108195
Johnson & Johnson	JNJ-87562761	—	ACTIVE NOT RECRUITING	2027-11-03	NCT06604715
Poseida Therapeutics, Inc.	P-BCMA-ALLO1 CAR-T cells	—	ACTIVE NOT RECRUITING	2029-03	NCT04960579
Roche	Cevostamab	—	ACTIVE NOT RECRUITING	2029-12-10	NCT04910568
Poseida Therapeutics, Inc.	Rimiducid may be administered as indicated	—	ACTIVE NOT RECRUITING	2032-08	NCT03741127
AbbVie	Etentamig	—	ACTIVE NOT RECRUITING	2033-09	NCT05259839
3D Medicines	3D189	—	ACTIVE NOT RECRUITING	2026-06	NCT05320809
AbbVie	Etentamig	—	ACTIVE NOT RECRUITING	2026-03	NCT05286229
Johnson & Johnson	Teclistamab	—	ACTIVE NOT RECRUITING	2025-10-13	NCT04722146
Pfizer	Elranatamab	BCMA/CD3	ACTIVE NOT RECRUITING	2025-07-07	NCT05675449
GSK	Belantamab mafodotin	—	ACTIVE NOT RECRUITING	2025-06-02	NCT04091126
Johnson & Johnson	Talquetamab	—	ACTIVE NOT RECRUITING	2025-05-22	NCT05338775
GSK	Belantamab mafodotin	—	ACTIVE NOT RECRUITING	2025-04-21	NCT04398745
Johnson & Johnson	Talquetamab	—	ACTIVE NOT RECRUITING	2025-03-31	NCT05050097
Kite, A Gilead Company	anitocabtagene-autoleucel	—	ACTIVE NOT RECRUITING	2024-10-03	NCT04155749
Hangzhou Sumgen Biotech Co., Ltd.	SG301	—	ACTIVE NOT RECRUITING	2024-06-30	NCT04684108
AbbVie	ABBV-453	—	ACTIVE NOT RECRUITING	2024-02-07	NCT05308654
Eli Lilly	LOXO-338	—	ACTIVE NOT RECRUITING	2023-06-14	NCT05024045
Celyad Oncology SA	CYAD-211	—	ACTIVE NOT RECRUITING	2022-12-21	NCT04613557
Bellicum Pharmaceuticals	BPX-501	—	ACTIVE NOT RECRUITING	2020-01-14	NCT02477878
Qilu Pharmaceutical Co., Ltd.	QL2109	—	NOT YET RECRUITING	2026-09	NCT07400744
Carbiogene Therapeutics Co. Ltd.	CBG002 CAR-T Cell Suspension	—	NOT YET RECRUITING	2027-10-25	NCT06705725
Suzhou Suncadia Biopharmaceuticals Co., Ltd.	SHR-5421 for Injection	—	NOT YET RECRUITING	2028-04	NCT07652281
Kure Cells, INC	Administration of CAR T-cells at 3 different dose levels	—	NOT YET RECRUITING	2028-09-30	NCT07611149
BrightPath Biotherapeutics Co., Ltd.	BP2202	—	NOT YET RECRUITING	2029-12-31	NCT07667868
GSK	Belantamab mafodotin	—	NOT YET RECRUITING	2031-08-22	NCT07609706
Qilu Pharmaceutical Co., Ltd.	QLS4131 Injection	—	NOT YET RECRUITING	2026-03-31	NCT06500507
Nanjing IASO Biotechnology Co., Ltd.	Fully human BCMA chimeric antigen receptor autologous T cell injection (CT103A)	—	NOT YET RECRUITING	2024-04	NCT05181501
Compugen Ltd	Dose escalation: COM902 monotherapy.	—	COMPLETED	2026-04-01	NCT04354246
Takeda	TAK-079	—	COMPLETED	2026-03-25	NCT03984097
Roche	Forimtamig	—	COMPLETED	2026-03-17	NCT04557150
Roche	Cevostamab	—	COMPLETED	2026-01-07	NCT03275103
Juno Therapeutics, a Subsidiary of Celgene	CC-95266	—	COMPLETED	2025-12-22	NCT04674813
Arcus Biosciences, Inc.	AB308	—	COMPLETED	2025-08-25	NCT04772989
ORIC Pharmaceuticals	ORIC-533	—	COMPLETED	2025-03-03	NCT05227144
Allogene Therapeutics	ALLO-647	—	COMPLETED	2025-01-27	NCT04093596
Biohaven Pharmaceuticals, Inc.	—	—	COMPLETED	2025-01-10	NCT04634435
Pfizer	Maplirpacept	—	COMPLETED	2024-11-06	NCT05896774
Pfizer	maplirpacept (PF-07901801)	—	COMPLETED	2024-10-02	NCT05567887
Ionis Pharmaceuticals, Inc.	ION251	—	COMPLETED	2024-09-30	NCT04398485
Fate Therapeutics	FT576 (Allogenic CAR NK cells with BCMA expression)	—	COMPLETED	2024-09-20	NCT05182073
Roche	XmAb24306	—	COMPLETED	2024-07-10	NCT05243342
Juno Therapeutics, a Subsidiary of Celgene	CC-98633	—	COMPLETED	2024-07-03	NCT04394650
Baxter Healthcare Corporation	DOXIL/CAELYX	—	COMPLETED	2024-06-21	NCT05567601
Sanofi	isatuximab SAR650984 IV	—	COMPLETED	2024-03-27	NCT04045795
Shanghai Henlius Biotech	HLX15	—	COMPLETED	2024-03-16	NCT05679258
Sutro Biopharma, Inc.	STRO-001	—	COMPLETED	2024-02-15	NCT03424603
Pfizer	PF-06863135 monotherapy IV or SC	—	COMPLETED	2024-01-19	NCT03269136
Ichnos Sciences SA	ISB 1342	—	COMPLETED	2023-12-15	NCT03309111
Bristol-Myers Squibb	CC-122	—	COMPLETED	2023-11-21	NCT01421524
Wuhan YZY Biopharma Co., Ltd.	Y150	—	COMPLETED	2023-10-23	NCT05011097
Bristol-Myers Squibb	bb2121	—	COMPLETED	2023-06-07	NCT04196491
Mundipharma Research Limited	Tinostamustine	—	COMPLETED	2023-05-30	NCT02576496
Nektar Therapeutics	NKTR-255	—	COMPLETED	2023-04-24	NCT04136756
GSK	Belantamab mafodotin	—	COMPLETED	2023-04-06	NCT03828292
CASI Pharmaceuticals, Inc.	CID-103	—	COMPLETED	2023-01-19	NCT04758767

Novel Multiple Myeloma Drugs by Company (New molecular entities)

16 companies have an FDA-approved novel drug for Multiple Myeloma.

Johnson & Johnson 2 drugs

Fresenius Kabi 1 drug

Hikma 1 drug

KARYOPHARM THERAPS 1 drug

XPOVIO

SELINEXOR

NDA 2019

Bristol-Myers Squibb 1 drug

CELLTRION INC 1 drug

Takeda 1 drug

Pfizer 1 drug

AYRMID PHARMA 1 drug

MOTIXAFORTIDE ACETATE

NDA 2023

RENGENERON PHARMACEUTICALS, INC. 1 drug

LYNOZYFIC

LINVOSELTAMAB-GCPT

BLA 2025

+6 more companies

Reformulations (14 drugs) Click to expand

Reformulations are FDA-approved versions of existing molecules in new dosage forms (e.g., oral solution vs tablet, extended-release vs immediate-release). They require a new NDA but use an already-proven active ingredient.

Multiple Myeloma Drug Targets

Molecular targets of approved and investigational Multiple Myeloma drugs — 16 targets tracked.

DNA 8 RANKL 8 Cereblon 5 BCMA 4 CD3 4 CXCR4 3 RNA 2 CD38 2 Hyaluronan 1 20S proteasome 1 XPO1 1 SLAMF7 1 26S proteasome 1 proteins 1 Proteasome 1 +1 more

Biosimilars (1 BLA approved) Click to expand

Biosimilars are biological products highly similar to FDA-approved reference biologics with no clinically meaningful differences in safety, purity, or potency.

OZILTUS

AMNEAL PHARMS

2025

Generic Drugs (7 ANDA approved) Click to expand

Generic drugs contain the same active ingredient as the brand-name drug and are approved via ANDA (Abbreviated New Drug Application).